Table 3.
Multivariate analysis of factors associated with mortality among HIV-infected adults on antiretroviral therapy
| Multivariate Results (n = 23890) | ||||||||
|---|---|---|---|---|---|---|---|---|
| 6 months | 12 months | 24 months | 36 months | |||||
| (n = 23890) | aOR (95% CI) | P value | aOR (95% CI) | P value | aOR (95% CI) | P value | aOR (95% CI) | P value |
| Gender | ||||||||
| Male | 1.66 (1.38–2.00) | < 0.001 | 1.59 (1.35–1.87) | < 0.001 | 1.56 (1.35–1.80) | < 0.001 | 1.59 (1.39–1.83) | < 0.001 |
| Female | Ref | Ref | Ref | Ref | ||||
| Age groups | ||||||||
| 20–35 | Ref | Ref | Ref | Ref | ||||
| 36–50 | 1.06 (0.88–1.28) | 0.545 | 1.15 (0.97–1.37) | 0.098 | 1.10 (0.95–1.27) | 0.223 | 1.09 (0.94–1.25) | 0.248 |
| 51+ | 1.34 (1.00–1.78) | 0.047 | 1.54 (1.2–1.98) | 0.001 | 1.52 (1.22–1.90) | < 0.001 | 1.51 (1.23–1.86) | < 0.001 |
| Marital Status | ||||||||
| Single | 1.30 (1.00–1.68) | 0.05 | 1.34 (1.07–1.68) | 0.01 | 1.36 (1.12–1.65) | 0.002 | 1.36 (1.13–1.63) | 0.001 |
| Divorced | 1.99 (1.58–2.51) | < 0.001 | 1.86 (1.52–2.28) | < 0.001 | 1.80 (1.50–2.15) | < 0.001 | 1.86 (1.56–2.22) | < 0.001 |
| Married | Ref | Ref | Ref | Ref | ||||
| Widowed | 1.33 (0.99–1.78) | 0.055 | 1.14 (0.88–1.49) | 0.330 | 1.23 (0.98–1.55) | 0.071 | 1.26 (1.01–1.58) | 0.041 |
| BMI | ||||||||
| < 18.5 | 1.65 (1.32–2.06) | < 0.001 | 1.57 (1.29–1.91) | < 0.001 | 1.55 (1.30–1.85) | < 0.001 | 1.54 (1.31–1.82) | < 0.001 |
| 18.5–24.9 | Ref | Ref | Ref | Ref | ||||
| 25–29.9 | 0.58 (0.37–0.9) | 0.015 | 0.62 (0.41–0.94) | 0.023 | 0.65 (0.46–0.92) | 0.014 | 0.68 (0.50–0.92) | 0.013 |
| 30+ | 0.41 (0.18–0.9) | 0.026 | 0.49 (0.26–0.92) | 0.027 | 0.57 (0.34–0.98) | 0.04 | 0.58 (0.36–0.94) | 0.027 |
| CD4 | ||||||||
| 0–250 | 2.66 (0.46–15.43) | 0.275 | 2.51 (0.53–12.00) | 0.249 | 1.59 (0.56–4.53) | 0.388 | 1.68 (0.59–4.77) | 0.331 |
| 251–500 | 1.56 (0.26–9.47) | 0.628 | 1.59 (0.33–7.76) | 0.565 | 0.94 (0.32–2.78) | 0.913 | 1.09 (0.37–3.18) | 0.873 |
| Above 500 | Ref | Ref | Ref | Ref | ||||
| Regimen Started | ||||||||
| D4T-based | Ref | Ref | Ref | Ref | ||||
| ABC-based | 0.95 (0.46–1.95) | 0.889 | 0.71 (0.35–1.45) | 0.346 | 0.60 (0.31–1.18) | 0.140 | 0.52 (0.26–1.02) | 0.056 |
| AZT-based | 1.02 (0.81–1.28) | 0.896 | 0.99 (0.80–1.21) | 0.887 | 0.89 (0.74–1.07) | 0.214 | 0.83 (0.70–0.99) | 0.04 |
| TDF-based | 0.58 (0.46–0.74) | < 0.001 | 0.57 (0.46–0.71) | < 0.001 | 0.57 (0.47–0.69) | < 0.001 | 0.55 (0.46–0.65) | < 0.001 |
| Baseline WHO Stage | ||||||||
| Stage I | Ref | Ref | Ref | Ref | ||||
| Stage II | 1.31 (0.86–2.01) | 0.214 | 1.32 (0.90–1.95) | 0.156 | 1.3 (0.93–1.83) | 0.130 | 1.25 (0.91–1.72) | 0.167 |
| Stage III | 2.27 (1.49–3.47) | < 0.001 | 2.29 (1.56–3.35) | < 0.001 | 2.11 (1.53–2.91) | < 0.001 | 1.94 (1.43–2.63) | < 0.001 |
| Stage IV | 5.29 (3.45–8.1) | < 0.001 | 5.10 (3.46–7.50) | < 0.001 | 4.79 (3.44–6.67) | < 0.001 | 4.24 (3.06–5.87) | < 0.001 |